Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Dibotermin alfa (Primary)
- Indications Bone disorders; Osteoarthritis
- Focus Therapeutic Use
- 27 Apr 2015 New trial record
- 19 Mar 2015 Status change from recruiting to active, not recruiting, as per ClinicalTrials.gov record.